The TWEAKR Enavatuzumab Biosimilar MAB (HDBS0031) is a monoclonal antibody designed for research involving TWEAKR, a cell surface receptor implicated in various biological processes, including cell proliferation, differentiation, and inflammation. This biosimilar antibody, developed as a therapeutic alternative, specifically targets TWEAKR to modulate its activity in immune regulation.Produced with high specificity and affinity, this antibody is ideal for use in various research applications, including cell signaling studies, immunohistochemistry, and flow cytometry. Its ability to bind specifically to TWEAKR allows for the detection and analysis of this receptor in different cell types, providing valuable insights into its role in immune response modulation and potential therapeutic interventions.
The TWEAKR Enavatuzumab Biosimilar MAB (HDBS0031) holds promise in advancing research into immune regulation, inflammation, and cancer biology. Its versatility and reliability make it a valuable tool for researchers seeking to further understand the intricate mechanisms of TWEAKR signaling and its implications in disease pathology and therapeutic development.
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
PDL 192
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
ELISA, Flow Cyt
Antibody Isotype:
IgG1
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
